(Q37786650)

23 August 2017

title

Atherosclerosis regression and high-density lipoproteins (English)

1 reference

23 August 2017

1 reference

1 reference

Justin M. S. Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828355

9 July 2024

Robin P. Choudhury

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828355

9 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20828355

9 July 2024

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

http://www.future-drugs.com/doi/abs/10.1586/erc.10.108

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20828355

http://www.tandfonline.com/doi/pdf/10.1586/erc.10.108

9 July 2024

1 reference

Expert Review of Cardiovascular Therapy

9 July 2024

published in

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1325-1334

1 reference

Atherosclerosis — An Inflammatory Disease

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Compensatory enlargement of human atherosclerotic coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Carotid plaque composition differs between ethno-racial groups: an MRI pilot study comparing mainland Chinese and American Caucasian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Cholesteryl ester transfer protein in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Dalcetrapib: a review of Phase II data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Apolipoprotein A-I mimetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

The role of dysfunctional HDL in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Mechanisms of disease: proatherogenic HDL--an evolving field

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.108

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

7

1 reference

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

9 July 2024

11

1 reference

High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells

9 July 2024

19

1 reference

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

9 July 2024

27

1 reference

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits

9 July 2024

29

1 reference

Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein

9 July 2024

32

1 reference

Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII

9 July 2024

33

1 reference

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

9 July 2024

37

1 reference

Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease

9 July 2024

40

1 reference

B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS)

9 July 2024

60

1 reference

A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients

9 July 2024

66

1 reference

Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells

9 July 2024

70

1 reference

Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport

9 July 2024

72

1 reference

Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia

9 July 2024

86

1 reference

Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study

9 July 2024

94

1 reference

Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice

9 July 2024

106

1 reference

9 July 2024

Identifiers

DOI

10.1586/ERC.10.108

1 reference

23 August 2017

1 reference